Chundong Gu
Mayo Clinic(US)Hong Kong Polytechnic University(HK)Dalian Medical University(CN)In-Q-Tel(US)First Affiliated Hospital of Dalian Medical University(CN)Affiliated Zhongshan Hospital of Dalian University(CN)Zhejiang University-University of Edinburgh Institute(CN)
Publications by Year
Research Areas
RNA modifications and cancer, Lung Cancer Diagnosis and Treatment, Lung Cancer Treatments and Mutations, Cancer-related molecular mechanisms research, RNA Research and Splicing
Most-Cited Works
- → Erlotinib Versus Gemcitabine Plus Cisplatin as Neoadjuvant Treatment of Stage IIIA-N2 EGFR-Mutant Non–Small-Cell Lung Cancer (EMERGING-CTONG 1103): A Randomized Phase II Study(2019)262 cited
- → SRSF1 modulates PTPMT1 alternative splicing to regulate lung cancer cell radioresistance(2018)168 cited
- → Prognostic Impact of Micrometastatic Tumor Cells in the Lymph Nodes and Bone Marrow of Patients With Completely Resected Stage I Non–Small-Cell Lung Cancer(2002)137 cited
- → Detection of Micrometastatic Tumor Cells in pN0 Lymph Nodes of Patients With Completely Resected Nonsmall Cell Lung Cancer(2002)134 cited
- → Overexpression of MACC1 mRNA in lung adenocarcinoma is associated with postoperative recurrence(2010)93 cited
- → Erlotinib versus gemcitabine plus cisplatin as neoadjuvant treatment of stage IIIA-N2 EGFR-mutant non-small-cell lung cancer: final overall survival analysis of the EMERGING-CTONG 1103 randomised phase II trial